276 related articles for article (PubMed ID: 33479693)
1. Recent developments of small molecule γ-secretase modulators for Alzheimer's disease.
Mekala S; Nelson G; Li YM
RSC Med Chem; 2020 Sep; 11(9):1003-1022. PubMed ID: 33479693
[TBL] [Abstract][Full Text] [Related]
2. Development and mechanism of γ-secretase modulators for Alzheimer's disease.
Crump CJ; Johnson DS; Li YM
Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767
[TBL] [Abstract][Full Text] [Related]
3. γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not.
Lessard CB; Rodriguez E; Ladd TB; Minter LM; Osborne BA; Miele L; Golde TE; Ran Y
Alzheimers Res Ther; 2020 May; 12(1):61. PubMed ID: 32430033
[TBL] [Abstract][Full Text] [Related]
4. Beta-amyloid precursor protein mutants respond to gamma-secretase modulators.
Page RM; Gutsmiedl A; Fukumori A; Winkler E; Haass C; Steiner H
J Biol Chem; 2010 Jun; 285(23):17798-810. PubMed ID: 20348104
[TBL] [Abstract][Full Text] [Related]
5. Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulators.
Jung JI; Ran Y; Cruz PE; Rosario AM; Ladd TB; Kukar TL; Koo EH; Felsenstein KM; Golde TE
Biochemistry; 2014 Apr; 53(12):1947-57. PubMed ID: 24620716
[TBL] [Abstract][Full Text] [Related]
6. γ-Secretase modulator in Alzheimer's disease: shifting the end.
Xia W; Wong ST; Hanlon E; Morin P
J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
[TBL] [Abstract][Full Text] [Related]
7. Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease.
Bulic B; Ness J; Hahn S; Rennhack A; Jumpertz T; Weggen S
Curr Neuropharmacol; 2011 Dec; 9(4):598-622. PubMed ID: 22798753
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
9. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo.
Huang Y; Li T; Eatherton A; Mitchell WL; Rong N; Ye L; Yang XJ; Jin S; Ding Y; Zhang J; Li Y; Wu Y; Jin Y; Sang Y; Cheng Z; Browne ER; Harrison DC; Hussain I; Wan Z; Hall A; Lau LF; Matsuoka Y
Neuropharmacology; 2013 Jul; 70():278-86. PubMed ID: 23485401
[TBL] [Abstract][Full Text] [Related]
10. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
11. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
12. Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead.
Kumar D; Ganeshpurkar A; Kumar D; Modi G; Gupta SK; Singh SK
Eur J Med Chem; 2018 Mar; 148():436-452. PubMed ID: 29477076
[TBL] [Abstract][Full Text] [Related]
13. γ-Secretase Modulators and APH1 Isoforms Modulate γ-Secretase Cleavage but Not Position of ε-Cleavage of the Amyloid Precursor Protein (APP).
Lessard CB; Cottrell BA; Maruyama H; Suresh S; Golde TE; Koo EH
PLoS One; 2015; 10(12):e0144758. PubMed ID: 26678856
[TBL] [Abstract][Full Text] [Related]
14. gamma-Secretase as a therapeutic target in Alzheimer's disease.
Guardia-Laguarta C; Pera M; Lleó A
Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
16. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
[TBL] [Abstract][Full Text] [Related]
17. Exploring the chemical space of gamma-secretase modulators.
Zettl H; Weggen S; Schneider P; Schneider G
Trends Pharmacol Sci; 2010 Sep; 31(9):402-10. PubMed ID: 20591508
[TBL] [Abstract][Full Text] [Related]
18. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
19. Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012.
Pettersson M; Stepan AF; Kauffman GW; Johnson DS
Expert Opin Ther Pat; 2013 Oct; 23(10):1349-66. PubMed ID: 23875696
[TBL] [Abstract][Full Text] [Related]
20. APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment.
Sjödin S; Andersson KK; Mercken M; Zetterberg H; Borghys H; Blennow K; Portelius E
Alzheimers Res Ther; 2015 Dec; 7(1):77. PubMed ID: 26689589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
